Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a manufacturing change.
Nitin Jain, MD
Advertisement
Nitin Jain, MD, is a professor of medicine in the department of leukemia at the University of Texas MD Anderson Cancer Center.
Articles by Nitin Jain, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
2
Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer
3
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
4
Orexin Agonist Shows Promise for Treating Narcolepsy, Hypersomnia: Richard Bogan, MD
5